The European Medicines Agency wants to suspend around 300 marketed generic meds (and applications) due to its concerns.

ArQule's lead drug has failed yet another late-stage trial, drawing a line under the program as the biotech tries to move beyond what CEO Paolo Pucci has…

Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline.

Ionis’ lipid disorder subsidiary Akcea Therapeutics has filed for a $100 million IPO and secured a $50 million stock purchase commitment from Novartis.

The Centers for Medicare & Medicaid Services published criteria for coverage of therapeutic continuous glucose monitoring systems.

Detecting DNA in blood is possible, but one major challenge is figuring out where in the body the cancer is hiding. Now UCLA researchers believe they’ve hit…

A new deal answers Lilly's concerns that Ignyta wasn't holding up its end of the license disease for taladegib.

A phase 2 trial of Xenon Pharmaceuticals’ acne candidate XEN801 has missed its primary and key secondary efficacy endpoints.

During his budget blueprint announced earlier this month, President Donald Trump announced swingeing cutbacks across federal programs, with the National…